DexComDXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
4% less repeat investments, than reductions
Existing positions increased: 321 | Existing positions reduced: 336
5% less call options, than puts
Call options by funds: $404M | Put options by funds: $423M
7.35% less ownership
Funds ownership: 95.27% [Q2] → 87.92% (-7.35%) [Q3]
13% less funds holding
Funds holding: 981 [Q2] → 851 (-130) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
45% less capital invested
Capital invested by funds: $42.9B [Q2] → $23.6B (-$19.3B) [Q3]
58% less first-time investments, than exits
New positions opened: 96 | Existing positions closed: 226
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Bernstein Lee Hambright 100% 1-year accuracy 1 / 1 met price target | 13%upside $86 | Outperform Maintained | 25 Oct 2024 |
Raymond James Jayson Bedford 67% 1-year accuracy 20 / 30 met price target | 30%upside $99 | Strong Buy Maintained | 25 Oct 2024 |
RBC Capital Shagun Singh 55% 1-year accuracy 43 / 78 met price target | 52%upside $115 | Outperform Maintained | 25 Oct 2024 |
Oppenheimer Steven Lichtman 50% 1-year accuracy 9 / 18 met price target | 38%upside $105 | Outperform Maintained | 25 Oct 2024 |
JP Morgan Robbie Marcus 63% 1-year accuracy 12 / 19 met price target | 12%upside $85 | Neutral Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 36 articles about DXCM published over the past 30 days
